These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 12297834

  • 1. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes.
    Huesker M, Folmer Y, Schneider M, Fulda C, Blum HE, Hafkemeyer P.
    Hepatology; 2002 Oct; 36(4 Pt 1):874-84. PubMed ID: 12297834
    [Abstract] [Full Text] [Related]

  • 2. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
    Kaszubiak A, Holm PS, Lage H.
    Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
    [Abstract] [Full Text] [Related]

  • 3. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
    Li B, Ye T, Zhao L, Li DH, Gou XH, Zhao LY, Han L, Chen L, Yan LN, Gong JP.
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
    [Abstract] [Full Text] [Related]

  • 4. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.
    Gao P, Zhou GY, Guo LL, Zhang QH, Zhen JH, Fang AJ, Lin XY.
    Cancer Lett; 2007 Oct 18; 256(1):81-9. PubMed ID: 17637500
    [Abstract] [Full Text] [Related]

  • 5. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
    Kobayashi H, Takemura Y, Miyachi H.
    Hum Cell; 2001 Sep 18; 14(3):172-84. PubMed ID: 11774737
    [Abstract] [Full Text] [Related]

  • 6. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs.
    Folmer Y, Schneider M, Blum HE, Hafkemeyer P.
    Cancer Gene Ther; 2007 Nov 18; 14(11):875-84. PubMed ID: 17704753
    [Abstract] [Full Text] [Related]

  • 7. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB, Yan ML, Gong JP, Xia RP, Liu LX, Li N, Lu SC, Zhang JG, Zeng DB, Xie JG, Yang JY, Yan LN.
    Chin Med J (Engl); 2007 Apr 20; 120(8):703-7. PubMed ID: 17517188
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.
    Nagata J, Kijima H, Hatanaka H, Asai S, Miyachi H, Abe Y, Yamazaki H, Nakamura M, Watanabe N, Mine T, Kondo T, Scanlon KJ, Ueyama Y.
    Int J Oncol; 2002 Nov 20; 21(5):1021-6. PubMed ID: 12370750
    [Abstract] [Full Text] [Related]

  • 10. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.
    Kobayashi H, Dorai T, Holland JF, Ohnuma T.
    Cancer Res; 1994 Mar 01; 54(5):1271-5. PubMed ID: 8118816
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemoprotection effect of multidrug resistance 1 (MDR1) gene transfer to hematopoietic progenitor cells and engrafted in mice with cancer allows intensified chemotherapy.
    Guo C, Jin X.
    Cancer Invest; 2006 Nov 01; 24(7):659-68. PubMed ID: 17118775
    [Abstract] [Full Text] [Related]

  • 13. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
    Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D.
    Clin Cancer Res; 2005 Jun 15; 11(12):4487-94. PubMed ID: 15958634
    [Abstract] [Full Text] [Related]

  • 14. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
    Gan HZ, Zhang GZ, Zhao JS, Zhang FC, Bu LS, Yang SJ, Piao SL, Du ZW, Gao S, Zheng DM.
    Chin Med J (Engl); 2005 Jun 05; 118(11):893-902. PubMed ID: 15978189
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter.
    Park SY, Kwak W, Thapa N, Jung MY, Nam JO, So IS, Kim SY, Yoo J, Lee J, Kim IS.
    J Nucl Med; 2008 Sep 05; 49(9):1480-8. PubMed ID: 18703598
    [Abstract] [Full Text] [Related]

  • 16. [Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter].
    Zhou HK, Yang DH, Tang SH, Huang W, Lu XH.
    Zhonghua Yi Xue Za Zhi; 2006 Jan 10; 86(2):106-10. PubMed ID: 16620715
    [Abstract] [Full Text] [Related]

  • 17. Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo.
    Guo CB, Li YC, Jin XQ.
    Cancer Chemother Pharmacol; 2006 Jul 10; 58(1):40-9. PubMed ID: 16284790
    [Abstract] [Full Text] [Related]

  • 18. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells.
    Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T.
    Hum Gene Ther; 1999 May 01; 10(7):1185-95. PubMed ID: 10340550
    [Abstract] [Full Text] [Related]

  • 19. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites.
    Kobayashi H, Takemura Y, Wang FS, Oka T, Ohnuma T.
    Int J Cancer; 1999 Jun 11; 81(6):944-50. PubMed ID: 10362143
    [Abstract] [Full Text] [Related]

  • 20. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
    Sugimoto Y, Tsukahara S, Sato S, Suzuki M, Nunoi H, Malech HL, Gottesman MM, Tsuruo T.
    J Gene Med; 2003 May 11; 5(5):366-76. PubMed ID: 12731085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.